The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study.
P. A. Cassier
No relevant relationships to disclose
V. Moreno Garcia
No relevant relationships to disclose
C. Gomez-Roca
No relevant relationships to disclose
D. Olmos
No relevant relationships to disclose
R. Morales
No relevant relationships to disclose
G. Del Conte
No relevant relationships to disclose
E. Gallerani
No relevant relationships to disclose
A. Brunetto
No relevant relationships to disclose
P. Schoffski
No relevant relationships to disclose
S. Marsoni
No relevant relationships to disclose
J. H. M. Schellens
No relevant relationships to disclose
N. Penel
No relevant relationships to disclose
E. E. Voest
No relevant relationships to disclose
T. R. J. Evans
No relevant relationships to disclose
R. Plummer
No relevant relationships to disclose
R. H. Wilson
No relevant relationships to disclose
J. Soria
No relevant relationships to disclose
J. Tabernero
No relevant relationships to disclose
J. Verweij
No relevant relationships to disclose
S. B. Kaye
No relevant relationships to disclose